{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:44:06Z","timestamp":1782794646415,"version":"3.54.5"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jare.2026.06.026","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T23:28:57Z","timestamp":1782170937000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A \u03b1-synuclein aggregation inhibitor exerts neuroprotective effects via mitochondrial resilience in Parkinson\u2019s disease"],"prefix":"10.1016","author":[{"given":"Ye","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junrui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6442-8191","authenticated-orcid":false,"given":"Naihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7626","key":"10.1016\/j.jare.2026.06.026_b0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/538S1a","article-title":"Parkinson's disease","volume":"538","author":"Grayson","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jare.2026.06.026_b0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1474-4422(21)00030-2","article-title":"Challenges in the diagnosis of Parkinson's disease","volume":"20","author":"Tolosa","year":"2021","journal-title":"Lancet Neurol"},{"issue":"10291","key":"10.1016\/j.jare.2026.06.026_b0015","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"520","key":"10.1016\/j.jare.2026.06.026_b0020","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba1659","article-title":"Promising disease-modifying therapies for Parkinson's disease","volume":"11","author":"Dawson","year":"2019","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.jare.2026.06.026_b0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: current strategies and future research priorities","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"Pt B","key":"10.1016\/j.jare.2026.06.026_b0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2017.07.018","article-title":"Distinct \u03b1-Synuclein strains and implications for heterogeneity among \u03b1-Synucleinopathies","volume":"109","author":"Peng","year":"2018","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.jare.2026.06.026_b0035","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1073\/pnas.1913904117","article-title":"The process of Lewy body formation, rather than simply \u03b1-synuclein fibrillization, is one of the major drivers of neurodegeneration","volume":"117","author":"Mahul-Mellier","year":"2020","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.jare.2026.06.026_b0040","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/iub.2194","article-title":"The good and bad of therapeutic strategies that directly target \u03b1-synuclein","volume":"72","author":"Longhena","year":"2020","journal-title":"IUBMB Life"},{"issue":"12","key":"10.1016\/j.jare.2026.06.026_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2023.167992","article-title":"Common Mechanisms underlying \u03b1-synuclein-induced mitochondrial dysfunction in Parkinson's disease","volume":"435","author":"Sohrabi","year":"2023","journal-title":"J Mol Biol"},{"issue":"11","key":"10.1016\/j.jare.2026.06.026_b0050","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1093\/brain\/awaa279","article-title":"Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy","volume":"143","author":"Lin","year":"2020","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.jare.2026.06.026_b0055","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00041.2021","article-title":"Mitochondrial quality control in health and in Parkinson's disease","volume":"102","author":"Eldeeb","year":"2022","journal-title":"Physiol Rev"},{"issue":"14","key":"10.1016\/j.jare.2026.06.026_b0060","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1074\/jbc.M710012200","article-title":"Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain","volume":"283","author":"Devi","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.jare.2026.06.026_b0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41467-018-03241-9","article-title":"Cardiolipin exposure onthe outer mitochondrial membrane modulates \u03b1-synuclein","volume":"9","author":"Ryan","year":"2018","journal-title":"Nat Commun"},{"issue":"41","key":"10.1016\/j.jare.2026.06.026_b0070","doi-asserted-by":"crossref","first-page":"10481","DOI":"10.1073\/pnas.1804198115","article-title":"Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons","volume":"115","author":"Pujols","year":"2018","journal-title":"PNAS"},{"issue":"41","key":"10.1016\/j.jare.2026.06.026_b0075","doi-asserted-by":"crossref","first-page":"28282","DOI":"10.1021\/jacs.4c08869","article-title":"Inhibitor Development for \u03b1-Synuclein Fibril's Disordered Region to Alleviate Parkinson's Disease Pathology","volume":"146","author":"Zhang","year":"2024","journal-title":"J Am Chem Soc"},{"issue":"1","key":"10.1016\/j.jare.2026.06.026_b0080","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1038\/s41467-022-32797-w","article-title":"The clinical drug candidate anle138b binds in a cavity of lipidic \u03b1-synuclein fibrils","volume":"13","author":"Antonschmidt","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.jare.2026.06.026_b0085","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41419-023-06116-0","article-title":"A small molecule 20C from Gastrodia elata inhibits \u03b1-synuclein aggregation and prevents progression of Parkinson's disease","volume":"14","author":"Peng","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jare.2026.06.026_b0090","doi-asserted-by":"crossref","first-page":"9862","DOI":"10.1038\/srep09862","article-title":"Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant \u03b1-Synuclein","volume":"5","author":"Ahsan","year":"2015","journal-title":"Sci Rep"},{"issue":"10423","key":"10.1016\/j.jare.2026.06.026_b0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","article-title":"The pathogenesis of Parkinson's disease","volume":"403","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jare.2026.06.026_b0100","unstructured":"Frisch, M., et al., Gaussian 09, revision D. 01. 2009, Gaussian, Inc., Wallingford CT."},{"key":"10.1016\/j.jare.2026.06.026_b0105","unstructured":"Wang, J., et al., Antechamber: an accessory software package for molecular mechanical calculations. 2001. 222(U403)."},{"issue":"8","key":"10.1016\/j.jare.2026.06.026_b0110","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J Chem Theory Comput"},{"issue":"43","key":"10.1016\/j.jare.2026.06.026_b0115","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J Phys Chem A"},{"issue":"17","key":"10.1016\/j.jare.2026.06.026_b0120","doi-asserted-by":"crossref","first-page":"9656","DOI":"10.1039\/D0CP00831A","article-title":"The application of the MM\/GBSA method in the binding pose prediction of FGFR inhibitors","volume":"22","author":"Chen","year":"2020","journal-title":"PCCP"},{"issue":"5","key":"10.1016\/j.jare.2026.06.026_b0125","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin Drug Discov"},{"issue":"2","key":"10.1016\/j.jare.2026.06.026_b0130","first-page":"217","article-title":"Approximate atomic surfaces from linear combinations of pairwise overlaps","volume":"20","author":"Weiser","year":"1999","journal-title":"(LCPO)"},{"issue":"1","key":"10.1016\/j.jare.2026.06.026_b0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1021\/ci100275a","article-title":"Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. the accuracy of binding free energy calculations based on molecular dynamics simulations","volume":"51","author":"Hou","year":"2011","journal-title":"J Chem Inf Model"},{"issue":"4","key":"10.1016\/j.jare.2026.06.026_b0140","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.jare.2026.06.026_b0145","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/bph.14091","article-title":"RTP801 is a critical factor in the neurodegeneration process of A53T alpha-synuclein in a mouse model of Parkinson's disease under chronic restraint stress","volume":"175","author":"Zhang","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jare.2026.06.026_b0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jocn.2021.11.002","article-title":"The increase of \u03b1-synuclein and alterations of dynein in A53T transgenic and aging mouse","volume":"96","author":"Wang","year":"2022","journal-title":"J Clin Neurosci"},{"issue":"1","key":"10.1016\/j.jare.2026.06.026_b0155","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1038\/s41467-021-25767-1","article-title":"Selective targeting of the TLR2\/MyD88\/NF-\u03baB pathway reduces \u03b1-synuclein spreading in vitro and in vivo","volume":"12","author":"Dutta","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jare.2026.06.026_b0160","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11481-017-9771-4","article-title":"Increase in mitochondrial biogenesis in neuronal cells by RNS60, a physically-modified saline, via phosphatidylinositol 3-kinase-mediated upregulation of PGC1\u03b1","volume":"13","author":"Chandra","year":"2018","journal-title":"J Neuroimmune Pharmacol"},{"issue":"11","key":"10.1016\/j.jare.2026.06.026_b0165","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.1007\/s12035-019-01649-y","article-title":"Activation of peroxisome proliferator-activated receptor-\u03b1 increases the expression of nuclear receptor related 1 protein (Nurr1) in dopaminergic neurons","volume":"56","author":"Gottschalk","year":"2019","journal-title":"Mol Neurobiol"},{"issue":"7794","key":"10.1016\/j.jare.2026.06.026_b0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","article-title":"Discriminating \u03b1-synuclein strains in Parkinson's disease and multiple system atrophy","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jare.2026.06.026_b0175","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1021\/cn400041j","article-title":"Structures and free energy landscapes of the A53T mutant-type \u03b1-synuclein protein and impact of A53T mutation on the structures of the wild-type \u03b1-synuclein protein with dynamics","volume":"4","author":"Coskuner","year":"2013","journal-title":"ACS Chem Nerosci"},{"issue":"1","key":"10.1016\/j.jare.2026.06.026_b0180","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12031-009-9289-1","article-title":"Establishment of stably transfected rat neuronal cell lines expressing alpha-synuclein GFP fusion proteins","volume":"41","author":"Schwach","year":"2010","journal-title":"J Mol Neurosci"},{"issue":"4","key":"10.1016\/j.jare.2026.06.026_b0185","doi-asserted-by":"crossref","first-page":"e1867","DOI":"10.1371\/journal.pone.0001867","article-title":"Formation of toxic oligomeric alpha-synuclein species in living cells","volume":"3","author":"Outeiro","year":"2008","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jare.2026.06.026_b0190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/abbs\/gms114","article-title":"Voltage-dependent anion channel involved in the \u03b1-synuclein-induced dopaminergic neuron toxicity in rats","volume":"45","author":"Lu","year":"2013","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"10","key":"10.1016\/j.jare.2026.06.026_b0195","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1111\/cns.14241","article-title":"Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats","volume":"29","author":"Bi","year":"2023","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"10.1016\/j.jare.2026.06.026_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104338","article-title":"Effects of beta-band and gamma-band rhythmic stimulation on motor inhibition","volume":"25","author":"Leunissen","year":"2022","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.jare.2026.06.026_b0205","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1515\/BC.2007.061","article-title":"Clinical chemistry reference database for Wistar rats and C57\/BL6 mice","volume":"388","author":"Boehm","year":"2007","journal-title":"Biol Chem"},{"key":"10.1016\/j.jare.2026.06.026_b0210","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3389\/fnmol.2019.00306","article-title":"ZPD-2, a small compound that inhibits \u03b1-synuclein amyloid aggregation and its seeded polymerization","volume":"12","author":"Pe\u00f1a-D\u00edaz","year":"2019","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"10.1016\/j.jare.2026.06.026_b0215","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41401-022-01039-6","article-title":"Pharmacological characterization of the small molecule 03A10 as an inhibitor of \u03b1-synuclein aggregation for Parkinson's disease treatment","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.jare.2026.06.026_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177774","article-title":"Inhibition of \u03b1-synuclein aggregation by MCC950 attenuates dopaminergic neuronal damage in MN9D cells","volume":"1001","author":"Gao","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jare.2026.06.026_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118262","article-title":"Comparative assessment of binding and functional differences of clinical antibodies targeting \u03b1-synuclein in cellular models of Parkinson's disease","volume":"189","author":"Liu","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jare.2026.06.026_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2024.105760","article-title":"The misfolding mystery: \u03b1-synuclein and the pathogenesis of Parkinson's disease","volume":"177","author":"Negi","year":"2024","journal-title":"Neurochem Int"},{"issue":"16","key":"10.1016\/j.jare.2026.06.026_b0235","doi-asserted-by":"crossref","first-page":"E1994","DOI":"10.1073\/pnas.1421204112","article-title":"Structural characterization of toxic oligomers that are kinetically trapped during \u03b1-synuclein fibril formation","volume":"112","author":"Chen","year":"2015","journal-title":"PNAS"},{"issue":"Pt 1","key":"10.1016\/j.jare.2026.06.026_b0240","article-title":"Structure specific neuro-toxicity of \u03b1-synuclein oligomer","volume":"253","author":"Mondal","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.jare.2026.06.026_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113722","article-title":"Insight into the molecular mechanism underlying the inhibition of \u03b1-synuclein aggregation by hydroxytyrosol","volume":"173","author":"Palazzi","year":"2020","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jare.2026.06.026_b0250","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41531-024-00835-7","article-title":"Push-pull effects of basal ganglia network in Parkinson's disease inferred by functional MRI","volume":"10","author":"Wang","year":"2024","journal-title":"NPJ Parkinsons Dis"},{"issue":"7879","key":"10.1016\/j.jare.2026.06.026_b0255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41586-021-03993-3","article-title":"The mouse cortico-basal ganglia-thalamic network","volume":"598","author":"Foster","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jare.2026.06.026_b0260","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41557-020-0465-9","article-title":"\u03b1-Synuclein aggregation nucleates through liquid-liquid phase separation","volume":"12","author":"Ray","year":"2020","journal-title":"Nat Chem"}],"container-title":["Journal of Advanced Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226005084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2090123226005084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:49:31Z","timestamp":1782791371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2090123226005084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"alternative-id":["S2090123226005084"],"URL":"https:\/\/doi.org\/10.1016\/j.jare.2026.06.026","relation":{},"ISSN":["2090-1232"],"issn-type":[{"value":"2090-1232","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A \u03b1-synuclein aggregation inhibitor exerts neuroprotective effects via mitochondrial resilience in Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Advanced Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jare.2026.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Cairo University.","name":"copyright","label":"Copyright"}]}}